Literature DB >> 3056121

Prostanoid production in varicose veins: evidence for decreased prostacyclin with increased thromboxane A2 and prostaglandin E2 formation.

G Biagi1, A Lapilli, R Zendron, L Piccinni, S Coccheri.   

Abstract

In this study, formation of arachidonic acid-derived prostanoids was investigated in saphenous veins of varicosed and nonvaricosed patients, all undergoing saphenectomy respectively for varicosis or in preparation for coronary bypass operation. Venous production of prostacyclin (PGI2), thromboxane A2 (TXA2) and prostaglandin E2 (PGE2) was assessed by bioassay and/or radioimmunologic assays as appropriate. Fragments of saphenous veins from varicosed patients produced significantly less PGI2 and more TXA2 and PGE2 than those from the control patients. Addition of arachidonic acid to incubation mixtures dose dependently increased release of these prostanoids, but the levels of PGI2 produced were consistently lower in veins from varicosed patients. No differences were found in varicosed patients between various segments of the same vein, no matter whether macroscopically affected or unaffected. These results demonstrate that the cyclooxygenase pathway in the venous wall of subjects with varicosis is shifted toward lesser formation of PGI2 and higher production of proaggregatory and proinflammatory prostanoids such as PGE2 and TXA2. These biochemical changes may be relevant to inflammation and thrombogenesis in varicosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3056121     DOI: 10.1177/000331978803901206

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  2 in total

1.  Prostacyclin release from the human saphenous vein in diabetics in lower than in nondiabetics.

Authors:  J S Brunkwall; D Bergqvist
Journal:  World J Surg       Date:  1992 Nov-Dec       Impact factor: 3.352

2.  Anti-Inflammatory and Anti-Vascular Leakage Effects by Combination of Centella asiatica and Vitis vinifera L. Leaf Extracts.

Authors:  Myung-Gi Seo; Min-Jeong Jo; Nam In Hong; Min Jung Kim; Kyu Suk Shim; Eunju Shin; Jeong Jun Lee; Sang-Joon Park
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-14       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.